Theophylline ER 450 mg study design [Design Issues]

posted by Ramesh Ramalingam  – India, 2018-10-18 07:16 (706 d 05:02 ago) – Posting: # 19463
Views: 1,286

Dear Members,

Based on literature reference, Theophylline is a narrow therapeutic index drug. As per USFDA recommendation if the drugs falls under narrow therapeutic index, the BE study should be a fully replicated crossover design in order to:
• Scale bioequivalence limits to the variability of the reference product; and
• Compare test and reference products within-subject variability.

But respective molecule OGD (which was issued on 2010) Draft guidelines recommending two-way cross-over study design.

Could you please suggest the study design whether it should be two-period, two-way crossover design or four period, fully replicated design.


Regards,
Ramesh

Complete thread:

Activity
 Admin contact
21,071 posts in 4,393 threads, 1,466 registered users;
online 22 (0 registered, 22 guests [including 2 identified bots]).
Forum time: Wednesday 12:19 CEST (Europe/Vienna)

The important thing in science is not so much to obtain new facts
as to discover new ways of thinking about them.    William Henry Bragg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5